{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T20:25:08Z","timestamp":1774902308925,"version":"3.50.1"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/coc.0b013e3182940dc3","type":"journal-article","created":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T13:18:46Z","timestamp":1367587126000},"page":"119-125","source":"Crossref","is-referenced-by-count":57,"title":["Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma"],"prefix":"10.1097","volume":"38","author":[{"given":"Derick","family":"Okwan-Duodu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian P.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad K.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-21-20210128","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":". Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R4-21-20210128","first-page":"1173","article-title":"Hahne M, et al..","volume":"99","author":"Saas","year":"1997","journal-title":"Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain J Clin Invest"},{"key":"R5-21-20210128","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1073\/pnas.0913496107","article-title":". Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.","volume":"107","author":"Larocque","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-21-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002371-200201000-00009","article-title":". Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.","volume":"25","author":"Guirguis","year":"2002","journal-title":"J Immunother"},{"key":"R7-21-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/OTT.S20257","article-title":". Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents.","volume":"4","author":"Khan","year":"2011","journal-title":"Onco Targets Ther"},{"key":"R8-21-20210128","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","article-title":". Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.","volume":"98","author":"Sambade","year":"2011","journal-title":"Radiother Oncol"},{"key":"R9-21-20210128","first-page":"385","article-title":"Swindell R, et al..","volume":"39","author":"Douglas","year":"2010","journal-title":"Mucosal melanoma of the head and neck: radiotherapy or surgery J Otolaryngol Head Neck Surg"},{"key":"R10-21-20210128","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hed.20901","article-title":". Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy.","volume":"30","author":"Meleti","year":"2008","journal-title":"Head Neck"},{"key":"R11-21-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cncr.11921","article-title":". Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck.","volume":"100","author":"Bonnen","year":"2004","journal-title":"Cancer"},{"key":"R12-21-20210128","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/1097-0142(19800501)45:9<2279::AID-CNCR2820450910>3.0.CO;2-H","article-title":"The radiotherapy of lentigo maligna and lentigo maligna melanoma of the head and neck.","volume":"45","author":"Dancuart","year":"1980","journal-title":"Cancer"},{"key":"R13-21-20210128","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":". The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.","volume":"119","author":"Diener-West","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R14-21-20210128","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cncr.20447","article-title":". Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity.","volume":"101","author":"Radbill","year":"2004","journal-title":"Cancer"},{"key":"R15-21-20210128","first-page":"4259","article-title":". Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases.","volume":"29","author":"Scorsetti","year":"2009","journal-title":"Anticancer Res"},{"key":"R16-21-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature11538","article-title":". Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"R17-21-20210128","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system.","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R18-21-20210128","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/PPO.0b013e3181eb3358","article-title":"Myeloid-derived suppressor cells in human cancer.","volume":"16","author":"Nagaraj","year":"2010","journal-title":"Cancer J"},{"key":"R19-21-20210128","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":". Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J Clin Oncol"},{"key":"R20-21-20210128","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.4049\/jimmunol.1200274","article-title":". Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.","volume":"189","author":"Kodumudi","year":"2012","journal-title":"J Immunol"},{"key":"R21-21-20210128","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":". 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"R23-21-20210128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00262-005-0018-5","article-title":". Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.","volume":"55","author":"Haanen","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"R24-21-20210128","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1038\/jid.2008.170","article-title":". CTLA-4 is a direct target of Wntbeta-catenin signaling and is expressed in human melanoma tumors.","volume":"128","author":"Shah","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R25-21-20210128","first-page":"416","article-title":"Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).","volume":"13suppl","author":"Weber","year":"2008","journal-title":"Oncologist"},{"key":"R26-21-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/156802612798919231","article-title":"Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.","volume":"12","author":"Lens","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"R27-21-20210128","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.","volume":"110","author":"ODay","year":"2007","journal-title":"Cancer"},{"key":"R28-21-20210128","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":". Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R29-21-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":". Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R30-21-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(02)00142-6","article-title":". Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.","volume":"84","author":"Ishida","year":"2002","journal-title":"Immunol Lett"},{"key":"R31-21-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":". Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"R32-21-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":". Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"R33-21-20210128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":". Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"R34-21-20210128","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":". Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 T cell dysfunction in melanoma patients.","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"R35-21-20210128","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ijc.26272","article-title":". PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.","volume":"130","author":"Kronig","year":"2012","journal-title":"Int J Cancer"},{"key":"R36-21-20210128","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":". Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"R37-21-20210128","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":". Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R38-21-20210128","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":". Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R39-21-20210128","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":". Therapeutic effects of ablative radiation on local tumor require CD8 T cells: changing strategies for cancer treatment.","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"R40-21-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":". Immunological aspects of cancer chemotherapy.","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"R41-21-20210128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":". Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"R42-21-20210128","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/0008-5472.CAN-08-0427","article-title":". Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.","volume":"68","author":"Apetoh","year":"2008","journal-title":"Cancer Res"},{"key":"R43-21-20210128","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":". Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol"},{"key":"R44-21-20210128","first-page":"234","article-title":"Whole body irradiation; radiobiology or medicine Br J Radiol.","volume":"26","author":"Mole","year":"1953","journal-title":""},{"key":"R45-21-20210128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1757-1626-2-204","article-title":". Abscopal effect in a patient with chronic lymphocytic leukemia during radiation therapy: a case report.","volume":"2","author":"Lakshmanagowda","year":"2009","journal-title":"Cases J"},{"key":"R46-21-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(99)80380-5","article-title":"The abscopal effect and chronic lymphocytic leukemia.","volume":"98","author":"Sham","year":"1995","journal-title":"Am J Med"},{"key":"R47-21-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/02841860600604611","article-title":". Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma.","volume":"45","author":"Wersall","year":"2006","journal-title":"Acta Oncol"},{"key":"R48-21-20210128","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/gut.43.4.575","article-title":". Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis.","volume":"43","author":"Ohba","year":"1998","journal-title":"Gut"},{"key":"R49-21-20210128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":". The abscopal effect associated with a systemic anti-melanoma immune response.","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R50-21-20210128","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":". Determinants of outcome in melanoma patients with cerebral metastases.","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"R51-21-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":". Immunologic correlates of the abscopal effect in a patient with melanoma.","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"R52-21-20210128","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":". gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"key":"R53-21-20210128","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":". Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R54-21-20210128","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":". Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R55-21-20210128","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":". Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"R56-21-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":". Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"key":"R57-21-20210128","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":". Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIcIV melanoma.","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R58-21-20210128","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":". Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase III study.","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R59-21-20210128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/scitranslmed.3003649","article-title":". Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.","volume":"4","author":"Seung","year":"2012","journal-title":"Sci Transl Med"},{"key":"R61-21-20210128","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2012.05.047","article-title":". Predictors of survival in contemporary practice after initial radiosurgery for brain metastases.","volume":"85","author":"Likhacheva","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e3182940dc3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:09:58Z","timestamp":1620950998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201502000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3182940dc3","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}